Welcome to our dedicated page for BIOHARVEST SCIENCES news (Ticker: CNVCF), a resource for investors and traders seeking the latest updates and insights on BIOHARVEST SCIENCES stock.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a pioneering biotechnology company with a focus on Botanical Synthesis. The company leverages its patented technology platform to produce plant-based molecules without the need to grow the underlying plant. BioHarvest is actively engaged in developing science-based and clinically proven therapeutic solutions in nutraceutical health and wellness products, including dietary supplements, and the creation of plant cell-based Active Pharmaceutical Ingredients (APIs) for specific medical indications. With a strong emphasis on innovation and research, BioHarvest aims to revolutionize the health and wellness industry with its cutting-edge products.
Rhea-AI Summary
BioHarvest Sciences Inc. announces its participation and sponsorship of the 2024 BIO CEO & Investor Conference in New York City. CEO Ilan Sobel will host meetings with investors and present the company's disruptive botanical synthesis platform. The company aims to accelerate growth and drive sustainable shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
-
Rhea-AI Summary
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) has reported robust revenue growth, gross margin expansion, and the launch of new product lines in 2023. The flagship product, VINIA®, is expected to drive record 2023 revenues of at least $12.4 million, representing a growth of at least 125% compared to 2022. The company aims to explore highly differentiated nutraceutical products using olive and pomegranate cells, expand geographically, and achieve profitability in 2024. BioHarvest is also making a commitment to engage with new investors and enhance long-term value for its shareholder partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioHarvest Sciences Inc. (BHSC) closed the second and final tranche of its non-brokered private placement of convertible notes, raising a total of CA$ 13,622,873.26. The successful financing allows the company to focus on profitability in 2024 and validates the significant Intellectual Property asset value created by the BioHarvest Sciences team and their platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
Rhea-AI Summary
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces the launch of VINIA Superfood Coffee, a disruptor in the $6B US coffee pod market. The company expects Q4 2023 revenue to range from USD 4.2M - 4.5M. The product line features VINIA Red Grape Superfood, known for improving blood flow, and has seen significant growth in revenues and customer base, with a 113% increase in Q3 revenues compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.67%
Tags
-
Rhea-AI Summary
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) announces Q3 Performance Update Presentation on December 13, 2023. CEO Ilan Sobel will discuss double-digit revenue growth, improved gross profit margins, and the upcoming launch of VINIA functional coffee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
-
Rhea-AI Summary
BioHarvest Sciences Inc (BHSC) announces Q3 2023 revenue of USD 3.24M for its flagship VINIA® product, representing 113% YoY growth and 18% QoQ growth. Gross profit margin improved to 45%. Total active VINIA® subscribers grew by 213% YoY. Q4 2023 revenue guidance is USD 4.2M - 4.5M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
Rhea-AI Summary
BioHarvest Sciences Inc. has closed the first tranche of its non-brokered private placement of convertible notes, raising CA$11,786,489.90 out of a total financing of up to CA$13.5M. The Convertible Notes have a term of 24 months and bear interest at 12% per annum. Holders can convert the notes into common shares at a conversion price equal to the closing market price of the company's shares on the date of conversion, with a discount of 20%. Major investors who invested $2,000,000 USD or more received warrants valid for two years. The company plans to use the proceeds to leverage growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
BioHarvest Sciences receives Canadian product license for VINIA® nutraceutical product
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioHarvest Sciences Inc announces that US sales of VINIA® in August have crossed the $1M per month line, validating its Botanical Synthesis technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
Rhea-AI Summary
BioHarvest Sciences Inc announces Q2 2023 results with revenues of USD 2.75M, representing 228% YoY growth and 27% QoQ growth. VINIA total active subscriber count grew by 620%. Gross product margins increased to 40% in Q2 2023. Cost of customer acquisition declined by 62% compared to Q2 2022. Net loss per share was USD 0.6. Cash flow break even targeted in late 2023, profitability in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
FAQ
What is the current stock price of BIOHARVEST SCIENCES (CNVCF)?
The current stock price of BIOHARVEST SCIENCES (CNVCF) is $5.99 as of October 14, 2024.
What is the market cap of BIOHARVEST SCIENCES (CNVCF)?
The market cap of BIOHARVEST SCIENCES (CNVCF) is approximately 83.2M.
What is the core business of BioHarvest Sciences Inc.?
BioHarvest Sciences Inc. focuses on Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules.
What are the main products of BioHarvest Sciences Inc.?
The company specializes in nutraceutical health and wellness products, including dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs).
What is BioHarvest Sciences Inc.'s approach to therapeutic solutions?
BioHarvest Sciences Inc. is committed to developing science-based and clinically proven therapeutic solutions using innovative botanical synthesis technology.
What are some recent achievements of BioHarvest Sciences Inc.?
Recent achievements include strong revenue growth, margin optimization, the launch of a Contract Development and Manufacturing Organization (CDMO) Services Business Unit, and signing contracts with notable pharmaceutical and food nutrition industry players.
What are BioHarvest Sciences Inc.'s future growth plans?
BioHarvest Sciences Inc. aims to achieve EBITDA break even in the second half of 2024, secure an uplisting to the Nasdaq Stock Market, and continue delivering shareholder value through product innovation and business expansion.
BIOHARVEST SCIENCES INC